Cansino Biologics Inc.

Jenkem Technology Co., Ltd.

Cansino (shanghai) Biological Research Co., Ltd.

Xuefeng Yu

Xuan Zhao

Meina Lin

Tao Zhu

Jian Liu

Zhongqi Shao

Yanli Xiong

Junqiang Li

Mingming Yang

Shengyong Yan

Lei Duan

Helen Huihua Mao

Jin Ma

Rong Jiang

Qingbin Wang

Huihua Mao

Chunlin Xin

Haiyan Cui

Weiwei Chen

Dongxu Qiu

Danqing Miao

Jing Hao

Zhihong Yan

Jun Guo

Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.

Cell strain for reducing production of replication competent adenovirus, and construction method and use thereof

Provided are a fusion protein and a construction method thereof. The fusion method consists of: aprotein D and a Hin47 (Htra) protein. The fusion protein can serve as a protein vehicle for apolysaccharide-protein conjugate vaccine, thereby increasing immunogenicity of a polysaccharide antigen.

fusion protein and construction method and use thereof

The invention provides an immunogenic composition for preventing pneumococcal diseases, comprising PspA-MRX1, PspA-EF5668, PspA-EF3296 and PlyL460D, wherein the amount of each component is 10-100 &#x3bc;g/ml; the immunogenic composition is prepared by adding to aluminum adjuvant the corresponding dosages of the four stock solutions PspA-mRX1, PspA-EF5668, PspA-EF3296 and PlyL460D, and mixing them homogeneously; the immunogenic composition can prevent infection and invasion by, covering more than 95% of the strains in clinic. The immunogenic composition has a wide application in the prevention of pneumonia, and is suitable for large-scale production in industry for its simple preparation method, low production cost, and short production cycle.

Immunogenic composition for preventing pneumococcal diseases and preparation method thereof

A method for enhancing immunogenicity of an epitope peptide of an HPV antigen, the method including: assembling a gene of an HPV antigen into a gene of HBc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the HPV antigen on a surface of the virus-like particle, to obtain HBc-HPV virus-like particle. A virus-like particle capable of expressing the antigen peptide of HPV acquired by the method. The virus-like particle includes a HBc-L2 fusion protein. A genome for encoding the HBc-L2 fusion protein is represented by SEQ ID NO. 3. A method for preparing an HPV vaccine includes using the virus-like particle.

Method for enhancing immunogenicity of epitope peptide of HPV antigen, virus-like particle, and method for preparing HPV vaccine

Growing community of inventors

Tianjin, China

Xuefeng Yu